Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:anaplastic_large_cell_lymphoma,_ALK-negative
gptkb:anaplastic_large_cell_lymphoma,_ALK-positive |
| gptkbp:activities |
gptkb:monoclonal_antibody
|
| gptkbp:appointed_by |
gptkb:hospital
intravenous infusion |
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
Phase II
combination therapy Phase III monotherapy NC T00848926 NC T01321592 NC T01776840 NC T02025050 NC T02210457 |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to brentuximab vedotin |
| gptkbp:developed_by |
gptkb:Seattle_Genetics
|
| gptkbp:effective_date |
August 19, 2011
|
| gptkbp:formulation |
lyophilized powder for reconstitution
|
| https://www.w3.org/2000/01/rdf-schema#label |
brentuximab vedotin
|
| gptkbp:indication |
relapsed or refractory systemic anaplastic large cell lymphoma
relapsed or refractory Hodgkin lymphoma |
| gptkbp:ingredients |
C649 H1008 N174 O198 S4
|
| gptkbp:interacts_with |
live vaccines
other immunosuppressants |
| gptkbp:is_a_route_for |
intravenous
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count neurological status |
| gptkbp:is_used_for |
treatment of Hodgkin lymphoma
treatment of systemic anaplastic large cell lymphoma |
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:marketed_as |
gptkb:Adcetris
|
| gptkbp:pharmacokinetics |
half-life of approximately 4 days
targeted delivery of cytotoxic agent |
| gptkbp:population |
adults
pediatric patients |
| gptkbp:provides_information_on |
ASCO guidelines
NCCN guidelines ECOG guidelines |
| gptkbp:research_areas |
gptkb:vaccine
oncology hematology |
| gptkbp:side_effect |
fatigue
nausea peripheral neuropathy infusion-related reactions neutropenia pulmonary toxicity tumor lysis syndrome |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:targets |
C D30
|
| gptkbp:type_of |
219978-17-5
|